A BILL 
To amend the Public Health Service Act to incentivize the 
manufacture of certain medicines in the United States 
and to enhance the security of the United States phar-
maceutical supply chain, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Enhancing the Secu-
4
rity of the U.S. Pharmaceutical Supply Chain Act of 
5
2020’’. 
6
04:16 Jan 08, 2021
H8987
2 
•HR 8987 IH
SEC. 2. TABLE OF CONTENTS. 
1
The table of contents for this Act is as follows: 
2
Sec. 1. Short title. 
Sec. 2. Table of contents. 
Sec. 3. Identification, development, and procurement of priority medicines. 
Sec. 4. Priority medicine production credit. 
Sec. 5. Improving regulatory efficiencies for transfer of drugs. 
SEC. 3. IDENTIFICATION, DEVELOPMENT, AND PROCURE-
3
MENT OF PRIORITY MEDICINES. 
4
(a) PRIORITY MEDICINES.—Title XXVIII of the Pub-
5
lic Health Service Act (42 U.S.C. 300hh et seq.) is amend-
6
ed by adding at the end the following: 
7
‘‘SEC. 2804. IDENTIFICATION OF PRIORITY MEDICINES. 
8
‘‘(a) PRIORITY MEDICINES.—The Secretary shall 
9
designate as a priority medicine each covered product 
10
that— 
11
‘‘(1)(A) is necessary for use in a public health 
12
emergency declared under section 319; or 
13
‘‘(B) is at high risk of becoming in short sup-
14
ply; and 
15
‘‘(2) has a vulnerable global supply chain. 
16
‘‘(b) GLOBAL SUPPLY CHAIN VULNERABILITY.—In 
17
determining whether a covered product has a vulnerable 
18
global supply chain under subsection (a)(2), the Secretary 
19
shall consider— 
20
‘‘(1) the findings of the National Academies of 
21
Sciences, Engineering, and Medicine in the report 
22
20:49 Jan 12, 2021
H8987
3 
•HR 8987 IH
published pursuant to section 4111 of the CARES 
1
Act (Public Law 116–136); 
2
‘‘(2) the number of manufacturers of each cov-
3
ered product; 
4
‘‘(3) the manufacturing locations, and amount 
5
produced, of each covered product; 
6
‘‘(4) the history of the importation of each pri-
7
ority medicine; and 
8
‘‘(5) the probability of the imposition of duties 
9
on the importation of each covered product. 
10
‘‘(c) CONSULTATION.—In carrying out subsection 
11
(a), the Secretary shall consult with the Public Health 
12
Emergency Medical Countermeasures Enterprise estab-
13
lished under section 2811–1. 
14
‘‘(d) PUBLICATION OF LIST.—The Secretary shall— 
15
‘‘(1) not later than 180 days after the date of 
16
enactment of this section, publish a preliminary list 
17
of priority medicines; 
18
‘‘(2) provide an opportunity for public comment 
19
on such preliminary list; 
20
‘‘(3) not later than 1 year after such date of en-
21
actment, publish a final list of priority medicines; 
22
and 
23
‘‘(4) on an annual basis, review and, as appro-
24
priate, update such list. 
25
04:16 Jan 08, 2021
H8987
4 
•HR 8987 IH
‘‘(e) DEFINITIONS.—In this section: 
1
‘‘(1) ACTIVE PHARMACEUTICAL INGREDIENT.— 
2
The term ‘active pharmaceutical ingredient’— 
3
‘‘(A) means any component that is in-
4
tended to furnish pharmacological activity or 
5
other direct effect in the diagnosis, cure, miti-
6
gation, treatment, or prevention of a disease, or 
7
to affect the structure or any function of the 
8
body of a human or animal; and 
9
‘‘(B) does not include— 
10
‘‘(i) intermediates used in the syn-
11
thesis of a drug product; or 
12
‘‘(ii) components that may undergo 
13
chemical change in the manufacture of a 
14
drug product and be present in a drug 
15
product in a modified form that is in-
16
tended to furnish such activity or effect. 
17
‘‘(2) COVERED PRODUCT.—The term ‘covered 
18
product’ means a drug (including a biological prod-
19
uct) or an active pharmaceutical ingredient. 
20
‘‘(3) PRIORITY MEDICINE.—The term ‘priority 
21
medicine’ means a priority medicine for which a des-
22
ignation is in effect under subsection (a).’’. 
23
(b) NATIONAL STRATEGIC HEALTH STRATEGY.— 
24
Section 2802(b) of the Public Health Service Act (42 
25
04:16 Jan 08, 2021
H8987
5 
•HR 8987 IH
U.S.C. 300hh–1(b)) is amended by adding at the end the 
1
following: 
2
‘‘(11) PRIORITY
MEDICINES.—Supporting the 
3
identification, production, and procurement of pri-
4
ority medicines designated under section 2804.’’. 
5
(c) PUBLIC HEALTH EMERGENCY MEDICAL COUN-
6
TERMEASURES ENTERPRISE RECOMMENDATIONS.—Sec-
7
tion 2811–1(c)(1) of the Public Health Service Act (42 
8
U.S.C. 300hh–10a(c)) is amended by adding at the end 
9
the following: 
10
‘‘(E) Provide recommendations to the Sec-
11
retary with respect to the priority medicines 
12
designated under section 2804.’’. 
13
(d) STRATEGIC PLAN FOR COUNTERMEASURE RE-
14
SEARCH, DEVELOPMENT, AND PROCUREMENT.—Section 
15
319L(b) of the Public Health Service Act (42 U.S.C. 
16
247d–7e(b)) is amended— 
17
(1) in paragraph (2)— 
18
(A) in subparagraph (B), by striking 
19
‘‘and’’ at the end; 
20
(B) in subparagraph (C), by striking the 
21
period at the end and inserting ‘‘; and’’; and 
22
(C) by adding at the end the following: 
23
04:16 Jan 08, 2021
H8987
6 
•HR 8987 IH
‘‘(D) the development and procurement of 
1
priority medicines designated under section 
2
2804.’’; and 
3
(2) by adding at the end the following: 
4
‘‘(3) PRIORITY
MEDICINES.—With respect to 
5
the development and procurement of priority medi-
6
cines, the Secretary shall promote a diverse and sus-
7
tainable supply chain, including through grants and 
8
purchases.’’. 
9
(e) CRITICAL DRUG CONSIDERATION.—Section 3101 
10
of the CARES Act (Public Law 116–136) is amended— 
11
(1) by redesignating subsection (d) as sub-
12
section (e); and 
13
(2) after executing the redesignation in para-
14
graph (1), by inserting after subsection (c) the fol-
15
lowing: 
16
‘‘(d) CONSIDERATION.—With respect to any analysis 
17
of a critical drug under subsection (b)(1), the Secretary 
18
shall consider the vulnerability of such drug with respect 
19
to the global supply chain, including an analysis of— 
20
‘‘(1) the number of manufacturers of such 
21
drug; 
22
‘‘(2) the manufacturing locations, and amounts 
23
produced, of such drug; 
24
04:16 Jan 08, 2021
H8987
7 
•HR 8987 IH
‘‘(3) the history of the importation of such 
1
drug; and 
2
‘‘(4) the probability of the imposition of duties 
3
on the importation of such drug.’’. 
4
SEC. 4. PRIORITY MEDICINE PRODUCTION CREDIT. 
5
(a) IN GENERAL.—Subpart D of part IV of sub-
6
chapter A of chapter 1 of the Internal Revenue Code of 
7
1986 is amended by adding at the end the following new 
8
section: 
9
‘‘SEC. 45U. PRIORITY MEDICINE PRODUCTION CREDIT. 
10
‘‘(a) GENERAL RULE.—For purposes of section 38, 
11
the priority medicine production credit determined under 
12
this section for the taxable year is an amount equal to 
13
50 percent of the qualified priority medicine expenses for 
14
the taxable year. 
15
‘‘(b) QUALIFIED PRIORITY MEDICINE EXPENSES.— 
16
‘‘(1) QUALIFIED
PRIORITY
MEDICINE
EX-
17
PENSES.—The term ‘qualified priority medicine ex-
18
penses’ means direct and indirect costs paid or in-
19
curred by the taxpayer during the taxable year for 
20
the production of priority medicines. 
21
‘‘(2) PRIORITY
MEDICINES.—For purposes of 
22
this section, a ‘priority medicine’ is a medicine that 
23
was included, within the 5 calendar years imme-
24
diately preceding the taxable year, on the list devel-
25
04:16 Jan 08, 2021
H8987
8 
•HR 8987 IH
oped and published by the Secretary of Health and 
1
Human Services pursuant to section 2804(d) of the 
2
Public Health Service Act. 
3
‘‘(3) COORDINATION WITH SECTION 263A.— 
4
‘‘(A) 
COORDINATION
WITH
SECTION 
5
263A.—In applying section 263A, indirect costs 
6
shall be allocated between the production of pri-
7
ority medicines and the production of other 
8
medicines based on the ratio in which the num-
9
ber of doses of the priority medicines produced 
10
in the taxable year bears to the total number of 
11
doses of all medicines produced by the taxpayer 
12
in that taxable year to which the expense is at-
13
tributable. 
14
‘‘(B) REGULATIONS AND GUIDANCE.—The 
15
Secretary shall by regulation or other guidance 
16
prescribe rules for the proper allocation of indi-
17
rect costs described in subparagraph (A).’’. 
18
(b) CREDIT ALLOWED AS BUSINESS CREDIT.—Sec-
19
tion 38(b) of the Internal Revenue Code of 1986 (relating 
20
to current year business credit) is amended by striking 
21
‘‘plus’’ at the end of paragraph (32), by striking the period 
22
at the end of paragraph (33) and inserting ‘‘, plus’’, and 
23
adding at the end the following new paragraph: 
24
04:16 Jan 08, 2021
H8987
9 
•HR 8987 IH
‘‘(34) the priority medicine production credit 
1
determined under section 45U.’’. 
2
(c) CONFORMING AMENDMENTS.— 
3
(1) COORDINATION WITH SECTION 59.— 
4
(A) Section 59A(b)(1)(B)(ii) is amended— 
5
(i) in subclause (I), by striking 
6
‘‘plus,’’ at the end; 
7
(ii) in subclause (II), by striking the 
8
period at the end, and inserting ‘‘, plus’’; 
9
and 
10
(iii) by adding at the end the fol-
11
lowing: 
12
‘‘(III) the credit allowed under 
13
section 38 for the taxable year which 
14
is properly allocable to the priority 
15
medicine production credit determined 
16
under section 45U.’’. 
17
(B) Section 59A(b)(2)(B) is amended to 
18
read as follows: 
19
‘‘(B) by reducing (but not below zero) the 
20
regular tax liability (as defined in section 
21
26(b)) for purposes of subparagraph (B) there-
22
of by the excess (if any) of the aggregate 
23
amount of the credits allowed under this chap-
24
ter against such regular tax liability over the 
25
04:16 Jan 08, 2021
H8987
10 
•HR 8987 IH
credit allowed under section 38 for the taxable 
1
year which is properly allocable to the priority 
2
medicine production credit determined under 
3
section 45U, rather than the excess described in 
4
such paragraph.’’. 
5
(2) COORDINATION WITH RESEARCH CREDIT.— 
6
Section 41(c)(4)(A) is amended by striking ‘‘14’’ 
7
and inserting ‘‘20’’. 
8
(d) CLERICAL AMENDMENT.—The table of sections 
9
for subpart D of part IV of subchapter A of part IV of 
10
subchapter A of chapter 1 of the Internal Revenue Code 
11
of 1986 is amended by inserting after the item relating 
12
to section 45T the following new item: 
13
‘‘Sec. 45U. Priority medicine production credit.’’ 
(e) EFFECTIVE DATE.—The amendments made by 
14
this section shall apply to qualified priority medicine ex-
15
penses paid or incurred after December 31, 2020. 
16
SEC. 5. IMPROVING REGULATORY EFFICIENCIES FOR 
17
TRANSFER OF DRUGS. 
18
The Federal Food, Drug, and Cosmetic Act (21 
19
U.S.C. 301 et seq.) is amended by inserting after section 
20
505–1 of such Act (21 U.S.C. 355–1) the following: 
21
‘‘SEC. 505–2. TRANSFER OF DRUGS TO DOMESTIC ESTAB-
22
LISHMENTS. 
23
‘‘(a) IN GENERAL.—Beginning not later than 90 
24
days after the date of the enactment of this section, the 
25
04:16 Jan 08, 2021
H8987
11 
•HR 8987 IH
Secretary shall expedite the review and approval of a sup-
1
plemental application to an abbreviated new drug applica-
2
tion approved under section 505(j) or a new drug applica-
3
tion approved under section 505(c) that seeks to transfer 
4
manufacturing of one or more finished dosage forms of 
5
a drug or one or more active pharmaceutical ingredients 
6
therein from one or more foreign establishments to one 
7
or more new or existing domestic establishments. 
8
‘‘(b) BEFORE SUPPLEMENTAL APPLICATION SUB-
9
MISSION.— 
10
‘‘(1) DEVELOPMENT
AND
PRE-SUBMISSION.— 
11
After an applicant submits a meeting request with 
12
respect to expedited review and approval of a supple-
13
mental application pursuant to subsection (a), the 
14
Secretary shall— 
15
‘‘(A) not later than 30 days after receiving 
16
such request, conduct a meeting with the appli-
17
cant to— 
18
‘‘(i) discuss the information necessary 
19
to approve the supplemental application; 
20
and 
21
‘‘(ii) if applicable, schedule a pre-ap-
22
proval inspection; and 
23
04:16 Jan 08, 2021
H8987
12 
•HR 8987 IH
‘‘(B) not later than 60 days after receiving 
1
such request, conduct a meeting with the appli-
2
cant to— 
3
‘‘(i) provide advice to the applicant 
4
with respect to the supplemental applica-
5
tion; and 
6
‘‘(ii) if applicable, select a first drug 
7
to be identified in accordance with sub-
8
section (c). 
9
‘‘(2) REVIEW AND APPROVAL.—In carrying out 
10
subsection (a), the Secretary shall— 
11
‘‘(A) review and take action with respect to 
12
a supplemental application not later than 6 
13
months after the date of submission or resub-
14
mission of such application; and 
15
‘‘(B) where the Secretary recommends a 
16
change to a domestic establishment following an 
17
inspection of such establishment, reinspect the 
18
establishment not later than 90 days after re-
19
ceiving a request from the applicant for rein-
20
spection. 
21
‘‘(3) 
RELATION
TO
FEE
PERFORMANCE 
22
GOALS.—The deadlines specified in paragraph (1) 
23
supersede any conflicting performance goals identi-
24
fied in any statute reauthorizing the fee programs in 
25
04:16 Jan 08, 2021
H8987
13 
•HR 8987 IH
parts 2 and 7 of subchapter C of title VII of the 
1
Federal Food, Drug, and Cosmetic Act. 
2
‘‘(c) CONTENTS.—With respect to a supplemental ap-
3
plication under subsection (a) for a transfer of the site 
4
of manufacture of multiple drugs that share a similar 
5
manufacturing process, the Secretary shall— 
6
‘‘(1) request a list of the drugs; 
7
‘‘(2) from the list under paragraph (1), identify 
8
a first drug to be transferred; 
9
‘‘(3) determine the criteria necessary to receive 
10
approval of the supplemental application; and 
11
‘‘(4) require the applicant to demonstrate, as 
12
part of such criteria, that each foreign establishment 
13
from which the drugs are to be transferred has a 
14
satisfactory inspection history with respect to the 
15
drugs. 
16
‘‘(d) SUBSEQUENT TRANSFER
OF DRUGS THAT 
17
SHARE A SIMILAR MANUFACTURING PROCESS.—After the 
18
approval of a supplemental application under subsection 
19
(a) for the transfer of the manufacturing of a first drug 
20
identified by the Secretary pursuant to subsection (c)(2) 
21
from one or more foreign establishments to one or more 
22
new or existing domestic establishments, the Secretary 
23
may allow the applicant to so transfer drugs that share 
24
a similar manufacturing process with such first drug pur-
25
04:16 Jan 08, 2021
H8987
14 
•HR 8987 IH
suant to submission of a report under section 506A(d)(2) 
1
rather than by requiring submission of a supplemental ap-
2
plication. 
3
‘‘(e) WORKING GROUP.— 
4
‘‘(1) ESTABLISHMENT.—Not later than 90 days 
5
after the date of enactment of this section, the Sec-
6
retary shall establish an intra-agency working group 
7
to be known as the Facility Transfer Working 
8
Group. 
9
‘‘(2) MEMBERSHIP.—The Secretary shall ap-
10
point members of the Facility Transfer Working 
11
Group from among officials and employees of the 
12
Department of Health and Human Services who— 
13
‘‘(A) represent a cross-section of the De-
14
partment of Health and Human Services; and 
15
‘‘(B) have expertise on establishments used 
16
to manufacture drugs. 
17
‘‘(3) DUTIES.—The Facility Transfer Working 
18
Group shall— 
19
‘‘(A) assist the Secretary in carrying out 
20
this section; 
21
‘‘(B) upon request by an applicant, con-
22
duct an informational site visit during the de-
23
velopmental phase to discuss requirements with 
24
04:16 Jan 08, 2021
H8987
15 
•HR 8987 IH
the applicant with respect to facility design, site 
1
status, and validation; 
2
‘‘(C) not later than 30 days after con-
3
ducting an informational site visit under sub-
4
paragraph (B), provide advice and feedback to 
5
the applicant with respect to facility issues that 
6
may prevent approval of the supplemental ap-
7
plication under subsection (a), including any 
8
issues with the facility transfer plans; and 
9
‘‘(D) participate in any pre-approval in-
10
spection required by the Secretary for an estab-
11
lishment or provide feedback to the Secretary 
12
with respect to a supplemental application de-
13
scribed in subsection (a). 
14
‘‘(f) ADDITIONAL INFORMATIONAL VISITS.—Upon 
15
request by the applicant, the Secretary may conduct infor-
16
mational site visits in addition to an informational site 
17
visit conducted by the Facility Transfer Working Group 
18
under subsection (e). 
19
‘‘(g) GUIDANCE.— 
20
‘‘(1) ISSUANCE.—Not later than 1 year after 
21
the date of enactment of this section, the Secretary 
22
shall issue guidance with respect to this section. 
23
‘‘(2) CONTENT.—The guidance issued under 
24
this paragraph shall include— 
25
04:16 Jan 08, 2021
H8987
16 
•HR 8987 IH
‘‘(A) the process by which an applicant 
1
may seek expedited review and approval of a 
2
supplemental application under subsection (a); 
3
and 
4
‘‘(B) a description of the actions the Sec-
5
retary may take to expedite the submission and 
6
review of such supplemental application. 
7
‘‘(h) DEFINITIONS.—In this section: 
8
‘‘(1) SATISFACTORY
INSPECTION
HISTORY.— 
9
The term ‘satisfactory inspection history’ means, 
10
with respect to a drug, a history consisting of one 
11
or more inspections in which the most recent manu-
12
facturing inspection was a satisfactory manufac-
13
turing inspection during which— 
14
‘‘(A) no objectionable conditions or prac-
15
tices were found; or 
16
‘‘(B) objectionable conditions were found 
17
and voluntary corrective action was left to the 
18
manufacturer. 
19
‘‘(2) SIMILAR MANUFACTURING PROCESS.—The 
20
term ‘similar manufacturing process’ means proc-
21
esses used to manufacture drugs that share at least 
22
one unit operation having the same design prin-
23
ciple.’’. 
24
Æ 
04:16 Jan 08, 2021
H8987
